Evaluation of the effect of silymarin on hepatotoxicity induced by Remdesivir

Phase 3

• Conditions: COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20201227049854N1
• Lead Sponsor: Shahre-kord University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 August 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Patients with positive covid19 PCR test who have been treated with Remdesivir
Spo2<93%
Patient with lung infiltration
Absence of underlying liver disease
Liver enzymes less than 5 times normal

Exclusion Criteria

Increased liver enzymes more than 5 times normal
Patient dissatisfaction
Pregnant or lactating patients
Patients with glomerular filtration less than 50 mg / min

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Direct Billirubin. Timepoint: Measurement of liver enzymes on the first and seventh days of the study. Method of measurement: Measurement of liver enzymes by BT 3500 device.;Total Billirubin. Timepoint: Measurement of liver enzymes on the first and seventh days of the study. Method of measurement: Measurement of liver enzymes by BT 3500 device.;Aspartate Aminotransferase. Timepoint: Measurement of liver enzymes on the first and seventh days of the study. Method of measurement: Measurement of liver enzymes by BT 3500 device.;Alanine Aminotransferase. Timepoint: Measurement of liver enzymes on the first and seventh days of the study. Method of measurement: Measurement of liver enzymes by BT 3500 device.;Alkaline Phosphatase. Timepoint: Measurement of liver enzymes on the first and seventh days of the study. Method of measurement: Measurement of liver enzymes by BT 3500 device.